Cytochrome P450 inactivation during reductive metabolism of 1,1-dichloro-2,2,2-trifluoroethane (HCFC-123) by phenobarbital- and pyridine-induced rat liver microsomes

Toxicology and Applied Pharmacology

Volumn 143, Issue 2, 1997, Pages 420-428

  Ferrara, Roberta ^a   Tolando, Roberto ^b   King, Laurence J ^b   Manno, Maurizio ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROFLUOROHYDROCARBON; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; GLUTATHIONE; HALOTHANE; PHENOBARBITAL; PYRIDINE; SCAVENGER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME INACTIVATION; ENZYME INDUCTION; LIVER MICROSOME; MALE; METABOLIC ACTIVATION; METABOLITE; NONHUMAN; RAT; REDUCTION; XENOBIOTIC METABOLISM;

EID: 0030998021     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1996.8064     Document Type: Article

References (51)

1. Ahr H. J., King L. J., Nastainczyk W., Ullrich V. The mechanism of reductive dehalogenation of halothane by liver cytochrome P450. Biochem. Pharmacol. 31:1982;383-390.
2. Albano E., Lott K. A. K., Slater T. F., Stier A., Symons M. C. R., Tomasi A. Spin-trapping studies on the free radical products formed by metabolic activation of carbon tetrachloride in rat liver microsomal fractions isolated hepatocytes andin vivo. Biochem. J. 204:1982;593-603.
3. Anders M. W. Metabolism and toxicity of hydrochlorofluorocarbons: Current knowledge and need for the future. Environ. Health Perspect. 96:1991;185-191.
4. Cooper D. Y., Cannon M. D., Scheyer H., Novack B. G., Rosenthal O. Anaerobic techniques for spectrophotometric studies of oxidative enzymes with low oxidation-reduction potentials. Hepatic Cytochrome P-450 Monooxygenase System. 1982;Pergamon Press, Oxford. p. 813-832.
5. Eckes L., Büch H. P. Influence of disulfiram, diethyldithiocarbamate and carbon disulfide on the metabolic formation of trifluoroacetic acid from halothane in the rat. Anzneim.-Forsch./Drug Res. 35:1985;1447-1451.
6. Falk J. E. Appendix 1. Absorption spectra. Falk J. E. Porphyrins and Metalloporphyrins. 1964;231-246 Elsevier, Amsterdam.
7. Fujii K., Morio M., Kikuchi H., Ishihara S., Okida M., Ficor F. In vivo. Life Sci. 35:1984;463-468.
8. Garle M. J., Fry J. R. Detection of reactive metabolites in vitro. Toxicology. 54:1989;101-110.
9. Godin C. S., Drerup J. M., Vinegar A. Conditions influencing the rat liver microsomal metabolism of 2,2-dichloro-1,1,1-trifluoroethane (HCFC-123). Drug Metab. Dispos. 21:1993;551-553.
10. Griffith O. W. Glutathione and glutathione disulphide. Bergmeyer H. U. Methods of Enzymatic Analysis. 1985;521-529 Verlag Chemie, Berlin.
11. Harris J. W., Anders M. W. Metabolism of the hydrochlorofluorocarbon 1,2-dichloro-1,1-difluoroethane. Chem. Res. Toxicol. 4:1991a;180-186.
12. Harris J. W., Anders M. W. In vivo. Biochem. Pharmacol. 41:1991b;R13-R16.
13. Harris J. W., Pohl L. R., Martin J. L., Anders M. W. Tissue acylation by the chlorofluorocarbon substitute 2,2-dichloro-1,1,1-trifluoroethane. Proc. Natl. Acad. Sci. USA. 88:1991;1407-1410.
14. Hildebrandt P., Garda H., Stier A., Stockburger M., Van Dyke R. Resonance Raman study of the cytochrome P-450 LM2-halothane intermediate complex. FEBS Lett. 237:1988;15-20.
15. Huwyler J., Aeschlimann D., Christen U., Gut J. The kidney as a novel target tissue for protein adduct formation associated with metabolism of halothane and the candidate chlorofluorocarbon replacement 2,2-dichloro-1,1,1-trifluoroethane. Eur. J. Biochem. 207:1992;229-238.
16. Huwyler J., Gut J. Exposure to the chlorofluorocarbon substitute 2,2-dichloro-1,1,1-trifluoroethane and the anaesthetic agent halothane is associated with transient protein adduct formation in the heart. Biochem. Biophys. Res. Commun. 184:1992;1344-1349.
17. Jarabek A. M., Fisher J. W., Rubenstein R., Lipscomb J. C., Williams R. J., Vinegar A., McDougal J. N. Mechanistic insights aid the search for CFC substitutes: Risk assessment of HCFC-123 as an example. Risk Anal. 14:1994;231-250.
18. Kenna J. G., Satoh H., Christ D. D., Pohl L. R. Metabolic bases for a drug hypersensitivity: Antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J. Pharmacol. Exp. Ther. 245:1988;1103-1109.
19. Koop D. R. Hydroxylation ofp. Mol. Pharmacol. 29:1986;399-404.
20. Lind R. C., Gandolfi A. J., Sipes I. G., Brown B. R., Water S. J. Oxygen concentrations required for reductive defluorination of halothane by rat hepatic microsomes. Anesth. Analg. 65:1986;835-839.
21. Lind R. C., Gandolfi A. J. Concentration dependent inhibition of halothane biotransformation and covalent binding in the guinea pig. Toxicologist. 12:1992;63.
22. Lind R. C., Gandolfi A. J. Concentration-dependent inhibition of halothane biotransformation in the guinea pig. Drug Metab. Dispos. 21:1993;386-389.
23. Lind R. C., Gandolfi A. J., De La M. Hall P. Biotransformation and hepatotoxicity of HCFC-123 in the guinea pig: Potentiation of hepatic injury prior to glutathione depletion. Toxicol. Appl. Pharmacol. 134:1995;175-181.
24. Loizou G. D., Urban G., Dekant W., Anders M. W. Gas-uptake pharmacokinetics of 2,2-dichloro-1,1,1-trifluoroethane (HCFC-123). Drug Metab. Disp. 22:1994;511-517.
25. Lowry O. H., Rosebrough N. J., Farr A. L., Randal R. J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
26. Lubet R. A., Mayer R. T., Cameron J. W., Nims R. W., Burke M. D., Wolff T., Guengerich F. P. Dealkylation of pentoxyresorufin: A rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat. Arch. Biochem. Biophys. 238:1985;43-48.
27. Malley L. A., Carakostas M., Hansen J. F., Rush G. M., Kelley D. P., Trochimowicz H. J. Two-year inhalation toxicity study in rats with hydrochlorofluorocarbon 123. Fundam. Appl. Toxicol. 25:1995;101-114.
28. Manno M., De Matteis F., King L. J. The mechanism of the suicidal, reductive inactivation of microsomal cytochrome P-450 by carbon tetrachloride. Biochem. Pharmacol. 37:1988;1981-1990.
29. Manno M. Suicidal inactivation of haem by halothane. Adv. Biosci. 76:1989;107-115.
30. Manno M., Cazzaro S., Rezzadore M. The mechanism of the suicidal reductive inactivation of microsomal cytochrome P-450 by halothane. Arch. Toxicol. 65:1991;191-198.
31. Manno M., Ferrara R., Cazzaro S., Rigotti P., Ancona E. Suicidal inactivation of human cytochrome P-450 by carbon tetrachloride and halothanein vitro. Pharmacol. Toxicol. 70:1992;13-18.
32. Marit G. B., Dodd D. E., George M. E., Vinegar A. Hepatotoxicity in guinea pigs following acute inhalation exposure to 1,1-dichloro-2,2,2-trifluoroethane. Toxicol. Pathol. 22:1994;404-414.
33. Mukai S., Morio M., Fujii K., Hanaki C. Volatile metabolites of halothane in the rabbit. Anaesthesiology. 47:1977;248-251.
34. Nastainczyk W., Ullrich V. Effect of oxygen concentration on the reaction of halothane with cytochrome P450 in liver microsomes and isolated perfused rat liver. Biochem. Pharmacol. 27:1978;387-392.
35. Olson M. J., Johnson J. T., O'Gara J. F., Surbrook S. E. Jr. Metabolismin vivoin vitro. Drug Metab. Dispos. 19:1991a;1004-1011.
36. Olson M. J., Kim S. G., Reidy C. A., Johnson J. T., Novak R. F. Oxidation of 1,1,1,2-tetrafluoroethane in rat liver microsomes in catalyzed primarily by cytochrome P-450IIE1. Drug Metab. Dispos. 19:1991b;298-303.
37. Olson M. J., Reidy C. A., Johnson J. T., Pederson T. C. Oxidative defluorination of 1,1,1,2-tetrafluoroethane by rat liver microsomes. Drug Metab. Dispos. 18:1990;992-998.
38. Omura T., Sato R. The carbon monoxide binding pigment of liver microsomes. J. Biol. Chem. 239:1964;2370-2378.
39. Paul K. G., Theorell H., Akeson A. The molar light absorption of pyridine ferroprotoporphyrin (pyridine haemochromogen). Acta Chem. Scand. 7:1953;1284-1287.
40. Rush G. M., Trochimowicz H. J., Malley L. A., Kelley D. P., Peckham J., Hansen J. F., Charm J. B. Subchronic inhalation toxicity studies with hydrochlorofluorocarbon 123 (HCFC-123). Fundam. Appl. Toxicol. 23:1994;169-178.
41. Sakai T., Yoshida H., Fukui A., Takaori M. Urinary and biliary excretion of metabolites of halothane in dogs. Drug Metab. Dispos. 19:1991;419-422.
42. Satoh H., Martin B. M., Schulick A. H., Christ D. D., Kenna J. C., Pohl L. R. Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase. Proc. Natl. Acad. Sci. USA. 86:1989;322-326.
43. Sawyer I. G., Eger E. I. II, Bahlman S. H., Cullen B. F., Impelman D. Concentration dependence of hepatic halothane metabolism. Anesthesiology. 34:1971;230-235.
44. Sharp J. H., Trudell J. R., Cohen E. N. Volatile metabolites and decomposition products of halothane in man. Anaesthesiology. 50:1979;2-8.
45. Tolando R., Cazzaro S., Ferrara R., Rezzadore M., Manno M. Reductive activation of halothane by human haemoglobin results in the modification of the prosthetic haem. Biochem. Pharmacol. 49:1995;233-241.
46. Tolando R., Ferrara R., Eldirdiri N. I., Albores A., King L. J., Manno M. Reductive activation of 1,1-dichloro-1-fluoroethane (HCFC-141b) by phenobarbital- and pyridine-induced rat liver microsomal cytochrome P450. Xenobiotica. 26:1996;425-435.
47. Tomasi A., Billing S., Garner A., Slater T. F., Albano E. The metabolism of halothane by hepatocytes: A comparison between free radical spin trapping and lipid peroxidation in relation to cell damage. Chem.-Biol. Interact. 46:1983;353-368.
48. Urban G., Dekant W. Metabolism of 1,1-dichloro-2,2,2-trifluoroethane in rats. Xenobiotica. 24:1994;881-892.
49. Urban G., Speerschneider P., Dekant W. Metabolism of the chlorofluorocarbon substitute 1,1-dichloro-2,2,2-trifluoroethane by rat liver microsomes: The role of cytochrome P450 2E1. Chem. Res. Toxicol. 7:1994;170-176.
50. Vinegar A., Williams R. J., Fisher J. W., McDougal J. N. Dose-dependent metabolism of 2,2-dichloro-1,1,1-trifluoroethane: A physiologically based pharmacokinetic model in the male fischer 344 rat. Toxicol. Appl. Pharmacol. 129:1994;103-113.
51. Partially Halogenated Chlorofluorocarbons (Ethane Derivatives). Environmental Health Criteria. 139:1992;World Health Organization, Geneva. p. 41-83.